About Biocon Limited
Biocon Limited (BIOCON) has been publicly traded since 2004, making it a 22-year-old public company. It operates in the Biotechnology industry within the Healthcare sector. The company is headquartered in Bengaluru, India. With a market capitalization of $621 billion, BIOCON is one of the largest publicly traded companies.
Key Statistics
- Current Price
- ₹383.55
- Market Cap
- ₹621.09B
- 52-Week High
- ₹424.95
- 52-Week Low
- ₹299.00
- Sector
- Healthcare
- Industry
- Biotechnology
₹1,000 Invested
Monthly Returns Heatmap
Annual Returns
| Year | Return | Start | End |
|---|---|---|---|
| 2026 | -2.63% | ₹393.90 | ₹383.55 |
| 2025 | +7.96% | ₹364.86 | ₹393.90 |
| 2024 | +46.55% | ₹248.97 | ₹364.86 |
| 2023 | -4.10% | ₹259.63 | ₹248.97 |
| 2022 | -28.08% | ₹360.97 | ₹259.63 |
| 2021 | -21.65% | ₹460.71 | ₹360.97 |
| 2020 | +58.46% | ₹290.74 | ₹460.71 |
| 2019 | -6.44% | ₹310.76 | ₹290.74 |
| 2018 | +17.28% | ₹264.98 | ₹310.76 |
| 2017 | +70.11% | ₹155.77 | ₹264.98 |
| 2016 | +85.29% | ₹84.07 | ₹155.77 |
| 2015 | +23.02% | ₹68.34 | ₹84.07 |
| 2014 | -7.11% | ₹73.57 | ₹68.34 |
| 2013 | +65.59% | ₹44.43 | ₹73.57 |
| 2012 | +6.92% | ₹41.55 | ₹44.43 |
| 2011 | -34.12% | ₹63.08 | ₹41.55 |
| 2010 | +54.15% | ₹40.92 | ₹63.08 |
| 2009 | +140.10% | ₹17.04 | ₹40.92 |
| 2008 | -59.09% | ₹41.65 | ₹17.04 |
| 2007 | +55.49% | ₹26.79 | ₹41.65 |
| 2006 | -24.00% | ₹35.25 | ₹26.79 |
| 2005 | -2.26% | ₹36.06 | ₹35.25 |
Valuation
BIOCON currently trades at a trailing P/E ratio of 78.8, which is considered high relative to the broader market. The forward P/E of 41.6 suggests analysts expect earnings to be lower in the coming year. The price-to-book ratio stands at 1.8. The price-to-sales ratio is 3.7.
Dividends
Biocon Limited pays a dividend to shareholders with a current yield of 0.13%. This translates to $0.50 per share annually. The payout ratio of 10% indicates sustainable dividend coverage.
Risk & Volatility
BIOCON has a beta of 0.21, indicating it is less volatile than the overall market. The stock's 52-week range is $299.00 to $424.95, and it currently trades in the upper half of its 52-week range.
Analyst Ratings
Based on 19 analyst opinions, BIOCON has a consensus "buy" rating. The average price target of $422.84 suggests 10.2% upside from current levels.
Frequently Asked Questions
What does Biocon Limited do? ▼
Biocon Limited is a Biotechnology company operating in the Healthcare sector. The company is headquartered in Bengaluru, India.
What sector is BIOCON in? ▼
BIOCON operates in the Healthcare sector, specifically in the Biotechnology industry.
When did BIOCON go public? ▼
Biocon Limited went public in 2004, making it a 22-year-old public company as of 2026.
How much would $1,000 invested in BIOCON 5 years ago be worth today? ▼
A $1,000 investment in BIOCON five years ago would be worth approximately $957 today, representing a -4.3% return.
Does BIOCON pay dividends? ▼
Yes, Biocon Limited pays a dividend with a current yield of 0.13%, which is $0.5 per share annually.
What is BIOCON's market cap? ▼
Biocon Limited has a market capitalization of $621 billion, classifying it as a mega-cap company.
What is BIOCON's P/E ratio? ▼
BIOCON has a trailing P/E ratio of 78.8 and a forward P/E of 41.6, which measures how much investors are paying per dollar of earnings.
Is BIOCON a buy, hold, or sell? ▼
Based on 19 opinions, BIOCON has a consensus "buy" rating. The average price target is $422.84.
Last updated: 3/14/2026